SLN (Silence Therapeutics) Tax Provision : $-1.10 Mil (TTM As of Dec. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Silence Therapeutics Tax Provision?

Silence Therapeutics's tax provision for the three months ended in Dec. 2024 was $-9.56 Mil. Its tax provision for the trailing twelve months (TTM) ended in Dec. 2024 was $-1.10 Mil.

Silence Therapeutics Tax Provision Historical Data

The historical data trend for Silence Therapeutics's Tax Provision can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Silence Therapeutics Tax Provision Chart

Silence Therapeutics Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Tax Provision

Get a 7-Day Free Trial

4.76

8.70

-0.69

-0.96

-0.85

Silence Therapeutics Quarterly Data
	Dec19	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Tax Provision	Get a 7-Day Free Trial															-8.87	1.88	2.38	4.21	-9.56

Silence Therapeutics Tax Provision Calculation

Tax to be paid.

Tax Provision for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.10 Mil.

Silence Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Silence Therapeutics PLC (NAS:SLN) » Definitions » Tax Provision

Comparable Companies

Traded in Other Exchanges

SLNCF:USA XRP2:Germany

Address

72 Hammersmith Road, London, GBR, W14 8TH

Website

https://www.silence-therapeutics.com

Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.